A Royal Visit for Innovative Leeds Charity
LHASA LIMITED RECOGNISED FOR ROLE IN SPEEDING UP DEVELOPMENT OF LIFE-SAVING DRUGS
His Royal Highness the Duke of Kent paid a special visit to an innovative Leeds-based charity, after it was awarded a Queen’s Award for Enterprise.
Lhasa Limited, which is based at Granary Wharf, is an educational charity which creates software that supports the pharmaceutical industry in bringing safe, effective and life enhancing medicines to market earlier. Lhasa was recognised by the Queen’s Awards in the Innovation category, in acknowledgement of its work with 350 of its members which include the world’s leading pharmaceutical companies, such as AstraZeneca, GlaxoSmithKline and Pfizer.
Founded in 1983 as a not-for-profit organisation and educational charity, to deliver public benefit through the collaborative development and use of computer aided reasoning in scientific software, Lhasa was initially based within the Chemistry department at the University of Leeds and employed only a handful of scientists. Today it is a fast-growing global organisation employing more than 130 people, with operations in Leeds, Poland and the USA. The growing global demand for its software has led to the opening of a new hub in Newcastle, which has generated a further eight jobs.
Visiting Lhasa to present the company with its award, the Duke was given a full tour of Lhasa’s headquarters and a special demonstration of the world - leading scientific software which won the award - Derek Nexus. This software is vitally important to the pharmaceutical sector as it predicts the toxicity of drugs and reduces the need for testing.
Lhasa’s development of Derek Nexus is credited with speeding up the development of some of the most important drugs to be released in the last 20 years.
The Queen's Awards for Enterprise are the UK's most prestigious accolades for business performance, and recognise and reward outstanding achievement. They are made each year by Her Majesty The Queen, on the recommendation of an advisory committee that includes representatives of Government, industry and commerce and trade unions.
The Innovation Award recognises companies who have delivered an outstanding performance as a result of an innovation.
David Watson, CEO of Lhasa Limited, said: “Winning the Queen’s Award for Enterprise will not only boost awareness of the work Lhasa Limited does in improving the development of safer drugs, but it will also highlight an important wider industry that is innovating all the time. We are constantly developing new computer-based approaches that keep the UK at the forefront of drug development”.
“We believe the work we do is very important, so it is great to be recognised. Our software equips the medical research community with the information they need to move their drug development work forward and prioritise which compounds they want to invest more time and money in - which means they can get their drugs to the public earlier, safely and potentially at a lower cost”.
“It was a real honour to welcome the Duke to Granary Wharf and gave our talented and hardworking team the opportunity to be part of this fantastic occasion.”
Notes to editors:
Lhasa Limited was founded in 1983 as not-for-profit organisation and educational charity. It facilitates collaborative data sharing projects in the pharmaceutical industry.
Lhasa specialises in the development of expert computer systems for toxicity and metabolism prediction. It provides a number of extensive and continually updated knowledge bases and the software needed to interrogate them.
Lhasa is a pioneer in the production of knowledge-based systems for forward thinking scientists, and continues to draw on its experience to create user-friendly, state of the art in silico prediction and database systems for use in metabolism, toxicology and related sciences.